Mumbai: Emerging pharma major Corona Remedies has reported a strong financial performance for the second quarter of Financial Year 2025-26, with its profit reaching ₹52.32 crore growing 21.8% from the same period last year. The company’s revenues have also increased to ₹361.13 crore, a 15.1% growth from last year.
The company has witnessed healthy growth on the back of its robust branded generics portfolio and its disciplined cost management strategies. The company maintains a strong presence in cardiology, diabetes management, pain management and women’s healthcare therapies. For investors, these results cement their trust in the company, whose listing in last month’s IPO saw them gain more than 35% of their investments.
“We are delighted to report a strong financial performance in Q2 and H1 FY26. Revenues for Q2 and H1FY26 grew by 15.1% and 17.0% respectively on a Y-o-Y basis, outperforming the IPM growth. Profit after tax for Q2 and H1FY26 grew by 21.8% and 35.1% respectively on a Y-o-Y basis while maintaining healthy return ratios,” Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said in a press release.
“Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.
Lastly, we are grateful to our bankers for their efforts in the successful listing of CORONA on the Indian stock exchanges. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.” he added.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in stocks includes financial risks, and past performance is not indicative of future results. Readers should conduct their own research or consult with a qualified financial advisor before making any investment decisions.
